Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03070145 · ClinicalTrials.gov registry record · NA

Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy

A NA study of Prostate Cancer, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
13
Enrollment target
1
Study location

NCT03070145: Completed NA study of Prostate Cancer, sponsored by Dana-Farber Cancer Institute.

NCT03070145 is a NA study of Prostate Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 13 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03070145, a NA study of Prostate Cancer, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating the impact and feasibility of a 12-week brisk walking and moderate strength training exercise intervention including a virtual component in men who are initiating androgen deprivation therapy (ADT) for prostate cancer

Primary Outcome

The 6 Minute Walk Test will be performed at the clinic, where the participants will wear tennis shoes and will walk indoors on a flat surface for 6 minutes.

Conditions Studied

Interventions

  • OTHER Exercise Intervention

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2017-12-08
Est. Completion 2019-12-12
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the finished NCT03070145 record still lists

NCT03070145 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Exercise Intervention is the first listed.

NCT03070145 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03070145 about?

NCT03070145 is a clinical study titled "Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy". This research study is evaluating the impact and feasibility of a 12-week brisk walking and moderate strength training exercise intervention including a virtual component in men who are initiating androgen deprivation therapy (ADT) for prostate cancer

What is the current status of trial NCT03070145?

This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2017-12-08. Estimated completion is 2019-12-12.

What conditions does trial NCT03070145 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03070145?

The interventions under investigation include: Exercise Intervention (OTHER).

Who is sponsoring clinical trial NCT03070145?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03070145 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03070145's enrollment target sits among peer trials

13 698th of 735 higher than 34 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03070145, the US trial registry maintained by the National Library of Medicine. NCT03070145 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.